Coherus Oncology Inc’s filing revealed that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.
UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock fall -1.67% to $0.77. Over the last five days, the stock has gained 1.31%. Coherus Oncology Inc shares have fallen nearly -44.49% since the year began. Nevertheless, the stocks have fallen -58.37% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 05/15/25. SMA at 50 days reached $0.9033, while 200 days put it at $1.1036.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 0.7474, which if violated will result in even more drops to 0.7287. On the upside, there is a resistance level at 0.7873. A further resistance level may holdings at 0.8085. The Relative Strength Index (RSI) on the 14-day chart is 39.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0027, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.55%. Stochastics %K at 23.82% indicates the stock is a holding.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
